2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 393

Association of Sex, Race and Ethnicity on Disease Outcomes in Juvenile Idiopathic Arthritis Patients
Abstract Number: 1757

Association of the Lupus Low Disease Activity State (LLDAS) with Health-Related Quality of Life
Abstract Number: 1260

Association of Traditional Chinese Medicine Use and Adherence to Prescribed Western Medications in Chinese-American Rheumatology Patients
Abstract Number: 3087

Association of Weight Loss with Improved Disease Activity in Patients with Rheumatoid Arthritis
Abstract Number: 1362

Associations Between 25-Hydroxyvitamin D, Parathyroid Hormone, and Cathelicidin Concentrations with Inflammation and Cardiovascular Risk in Subjects with Pediatric Systemic Lupus Erythematosus
Abstract Number: 2497

Associations Between Dietary Intake of Vitamin D, Omega-3 Fatty Acids, Folate and EULAR Response in Patients with Early Rheumatoid Arthritis
Abstract Number: 1486

Associations Between Heart Rate Adjusted ST Segment and Heart Rate Variability in Patients with Rheumatoid Arthritis
Abstract Number: 2886

Associations Between Type I Interferon and Antiphospholipid Antibody Status Differ Between Ancestral Backgrounds
Abstract Number: 2831

Associations of BAFF and Anti-BAFF Autoantibodies with Disease Activity in Oriental Systemic Lupus Erythematosus
Abstract Number: 1994

Associations of Chronic Lung Comorbidity with Medications, Disease Activity, and All-Cause Mortality in Rheumatoid Arthritis
Abstract Number: 1561

Associations of HLA-DRB1 Haplotypes with Disease Characteristics and All-Cause Mortality in Rheumatoid Arthritis
Abstract Number: 583

Associations of Serum Anti-Citrullinated Proteins and Cytokines with Radiographic Scores in African-American Rheumatoid Arthritis Patients
Abstract Number: 1350

Asymptomatic Coccidioidomycosis in Patients with Rheumatic Disease: 8 Years of Experience
Abstract Number: 764

Atacicept: Integrated Safety Profile from Phase II Randomized Placebo-Controlled Studies in Autoimmune Diseases
Abstract Number: 3182

Attenuation of Fluorine-18-Fluorodeoxyglucose Uptake in Large Vessel Giant Cell Arteritis after Short-Term High-Dose Steroid Treatment – a Diagnostic Window of Opportunity

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].